Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Launched by FUDAN UNIVERSITY · Dec 15, 2015

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with thymoma or thymic carcinoma who have had surgery but could not completely remove the tumor. The study aims to find out if adding chemotherapy and radiation therapy after surgery (called adjuvant radiochemotherapy) can help patients live longer compared to just using radiation therapy alone.

To participate, individuals must be between 18 and 75 years old and have had surgery that did not fully remove their tumor. They should also be in decent general health and have good function of their bone marrow, liver, and kidneys. Patients who have received other cancer treatments recently or have certain health issues may not be eligible. If you join the trial, you will receive either the combined treatment or just radiation therapy, and the outcomes will be closely monitored to see which method is more effective. This trial is currently looking for participants, and your involvement could help improve treatment options for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow, hepatic, and renal function;Patients receive incomplete resection within 3 months; Written informed consent.
• Exclusion Criteria:
• • Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.